Skip to main content

PMV Pharmaceuticals, Inc. (PMVP) Stock Forecast

Data as of May 2, 2026

Healthcare · Current price $1.38 (-0.72%)

Consensus Target
$18.00
Upside
+1204.3%
Analysts
Rating

Price Target Range

Low $5.00Consensus $18.00High $36.00
▲ Current $1.38

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

No rating trend data.

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Nov 8, 2024Jeff JonesOppenheimer$6.00+334.8%
Apr 11, 2024Kambiz YazdiJefferies$5.00+262.3%

PMVP vs Sector & Market

MetricPMVPHealthcare AvgLarge Cap Avg
Analyst Rating2.242.41
Analyst Count818
Target Upside+1204.3%+1148.8%+14.9%
P/E Ratio-0.976.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$3M$3M$3M4
2027-12-31$3M$3M$3M2
2028-12-31$24M$24M$24M2
2029-12-31$56M$56M$56M1
2030-12-31$155M$155M$155M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-1.62$-1.57$-1.492
2027-12-31$-1.21$-1.16$-1.102
2028-12-31$-0.82$-0.82$-0.821
2029-12-31$-0.58$-0.58$-0.581
2030-12-31$0.17$0.17$0.171

Frequently Asked Questions

What is the analyst consensus for PMVP?

The consensus among 0 analysts covering PMV Pharmaceuticals, Inc. (PMVP) is — with an average price target of $18.00.

What is the highest price target for PMVP?

The highest price target for PMVP is $6.00, set by Jeff Jones at Oppenheimer on 2024-11-08.

What is the lowest price target for PMVP?

The lowest price target for PMVP is $5.00, set by Kambiz Yazdi at Jefferies on 2024-04-11.

How many analysts cover PMVP?

0 analysts have issued ratings for PMV Pharmaceuticals, Inc. in the past 12 months.

Is PMVP a buy or sell right now?

Based on 0 analyst ratings, PMVP has a consensus rating of — with a +1204.3% upside to the consensus target of $18.00.

What are the earnings estimates for PMVP?

Analysts estimate PMVP will report EPS of $-1.57 for the period ending 2026-12-31, with revenue estimated at $3M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.